Universe Pharmaceuticals (UPC) Cash & Equivalents (2020 - 2025)

Universe Pharmaceuticals (UPC) has 6 years of Cash & Equivalents data on file, last reported at $33.6 billion in Q3 2025.

• For the quarter ending Q3 2025, Cash & Equivalents rose 13.88% year-over-year to $33.6 billion; the trailing twelve-month figure through Sep 2025 stood at $33.6 billion (up 13.88% YoY), and the FY2025 full-year result was $33.6 billion, up 13.88% from the prior year.
• Cash & Equivalents improved to $33.6 billion in Q3 2025, from $29.5 billion in the prior quarter.
• In the past five years, Cash & Equivalents ranged from a high of $33.6 billion in Q3 2025 to a low of $8.1 million in Q3 2021.
• A 5-year average of $9.3 billion and a median of $2.6 billion in 2022 frame the typical range for Cash & Equivalents.
• Across the five-year window, Cash & Equivalents soared 70604.67% in 2022 and tumbled 31.59% in 2024, its largest moves.
• Tracing UPC's Cash & Equivalents over 5 years: stood at $8.1 million in 2021, then soared by 70604.67% to $5.7 billion in 2022, then declined by 7.46% to $5.3 billion in 2023, then soared by 458.11% to $29.5 billion in 2024, then gained by 13.88% to $33.6 billion in 2025.
• Business Quant data shows UPC's Cash & Equivalents at $33.6 billion in Q3 2025, $29.5 billion in Q3 2024, and $8.9 million in Q1 2024.